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GITR is a member of the TNFR superfamily of proteins
and is expressed on resting regulatory T cells and on
other T cells, and NK cells, following activation. Signals
through GITR have been shown to drive increased T cell
activity and reduced regulatory T cell function. In order
to explore the potential of therapeutically targeting GITR
in a cancer setting, we generated a mouse GITRL fusion
protein (mGITRL FP) consisting of the extracellular
domain of mGITRL linked to a structural domain and an
IgG Fc domain. The antitumor activity and pharmacody-
namic effects of this molecule were then explored in the
colorectal syngeneic model of cancer (CT26).
Treatment of mice with mGITRL FP mediated anti-
tumor activity that was dependent on isotype and expo-
sure. The anti-tumour activity could be attributed at
least in part to the increased activation and proliferation
status of CD8+ and CD4+ T cells, as evidenced by
increases in Ki67 expression, ICOS upregulation and
increased cytokine secretion of these cells. Intratumou-
rally we observed a significant decrease in the frequency
of CD4+ T cells (including T regs), but a corresponding
increase in cytotoxic CD8+ T cells.
OX40 is another member of the TNFR superfamily,
that has similar expression and functions to GITR. In
order to better understand the potential differences
between targeting of these two pathways, the activity and
pharmacodynamic effects of the mGITRL FP were addi-
tionally compared and contrasted to those of a mOX40L
FP and the observed differences will be discussed.
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